Remicade: A Study In Translational Looping
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The lifecycle of J&J’s TNF inhibitor Remicade – a “pipeline in a product” – highlights how the company used the knowledge gained from one product to improve and expand its portfolio.
You may also be interested in...
FDA Panel Rejects Steroid-Sparing Claim For Remicade In Pediatric Ulcerative Colitis
Extrapolation from adult data does not work in this case and there is insufficient supporting pediatric data, the Gastrointestinal Drugs Advisory Committee concluded July 21.
Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers
Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class
J&J Celebrates Simponi Approval With Schering – For Now
As Schering waits to see if partner J&J will challenge Merck merger, FDA clears once-monthly follow-on to Remicade.